AF4 antibody (AA 31-130) (Cy7)
Quick Overview for AF4 antibody (AA 31-130) (Cy7) (ABIN760382)
Target
Reactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 31-130
-
Predicted Reactivity
- Human,Mouse,Rat,Rabbit
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human AF 4 protein
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- AF4 (AFF1) (AF4/FMR2 Family, Member 1 (AFF1))
-
Alternative Name
- AF4
-
Background
-
Synonyms: AF 4, AF 4 protein, AF-4 protein, AF4/FMR2 family member 1, AFF 1, AFF1, AFF1_HUMAN, ALL1 fused gene from chromosome 4, ALL1-fused gene from chromosome 4 protein, FEL, MLLT2, MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA TRANSLOCATED TO 2, MLLT2, Protein AF-4, Protein FEL, Proto-oncogene AF4.
Background: Proto-oncogene AF-4 (or FEL) is a product of a chromosomal aberration of the human gene AFF1, which is associated with acute leukemias. The fusion of AF-4 on chromosome band 4q21 with the mixed lineage leukemia (MLL or HRX) gene on 11q23 results in a MLL-AF-4 chimeric transcription factor in which AF-4 contributes transcriptional effector properties and requires cell-specific accessory factors. MLL is involved in several chromosomal translocations associated with acute myeloid and lymphoid leukemia. The MLL-AF-4 fusion protein is expressed in all normal hematopoietic cells. The expression of MLL-AF-4 influences the production of protein cyclin-dependent kinase inhibitor (CDKN1B), suggesting that inhibition of MLL-AF-4 expression may be a powerful and highly specific treatment of chemotherapy-resistant leukemia.
-
Gene ID
- 4299
Target
-